60% HFD Induced Obesity (DIO)

Comparison of Common Obesity Models

1. Drug efficacy of MGL-3196 and Semaglutide on DIO mice.

Figure 1. Semaglutide and MGL-3196 combination treatment enhances body weight loss in B6 DIO mice. Data are presented as Mean±SEM.

Figure 2. MGL-3196 does not affect food intake of DIO mice. Data are presented as Mean±SEM.

Figure 3. Combination treatment of MGL-3196 and Semaglutide significantly increases the reduction of fat mass in DIO mice while preserving lean mass. Data are presented as Mean±SEM. ns, not significant;  **, p<0.01;  ****, p<0.0001 by one way ANONA. 

Figure 4. MGL-3196 enhances energy expenditure in DIO mice. Data are presented as Mean±SEM. ns, not significant; **, p<0.01; ****, p<0.0001 by one way ANONA. 

2. Drug efficacy of Semaglutide and Bimagrumab on DIO mice.

Figure 5. Combination treatment of Bimagrumab and Semaglutide partially rescued Semaglutide’s association with lean mass loss and amplified fat mass loss. Data are presented as Mean±SEM. ns, not significant;. *, p<0.05;  ***, p<0.001; ****, p<0.0001 by one way ANONA. 

Figure 6. Bimagrumab drives skeletal muscle hypertrophy and preserves muscle mass during weight loss induced by Semaglutide. Data were presented as Mean±SEM.  ns, not significant;. *, p<0.05;  ***, p<0.001; ****, p<0.0001 by one way ANONA.